FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to conjugates containing interleukin 2 (IL2), mutant of tumor necrosis factor alpha (hereinafter – TNF-alpha) and an antibody molecule that binds fibronectin; it can be used in medicine for the treatment of malignant tumor.
EFFECT: invention provides an improvement in the tolerability of double immune-cytokine without changing the efficiency due to the use of TNF-alpha mutant with reduced activity.
15 cl, 5 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INCREASING IMMUNOGENICITY OF PROTEIN/PEPTIDE ANTIGEN | 2021 |
|
RU2830627C1 |
| KLK5-INHIBITING PEPTIDE | 2019 |
|
RU2826422C2 |
| METHOD FOR PRODUCTION OF ARENAVIRUS, AS WELL AS ARENAVIRUS MUTANTS WITH ANTITUMOR PROPERTIES | 2019 |
|
RU2812046C2 |
| ANTIBODY FOR SPECIFIC BINDING TO N-TERMINAL DOMAIN OF LYSYL-TRNA SYNTHETASE EXPOSED ON EXTRACELLULAR MEMBRANE | 2019 |
|
RU2781304C1 |
| F RSV PROTEIN MUTANTS | 2016 |
|
RU2788403C2 |
| PROTEIN F RSV MUTANTS | 2016 |
|
RU2723039C2 |
| FIMH ESCHERICHIA COLI MUTANTS AND USE THEREOF | 2021 |
|
RU2831010C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
